Last Updated on December 31, 2023 by The Health Master
Glenmark Pharma announced that it has received approval from the Drugs Controller General of India (DCGI) to conduct a phase-I clinical trial of its novel small molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
GRC 54276 is one of the many novel molecules from Glenmark’s resident, Innovative Medicines Group, headed by Dr Nikhil Amin, Chief Scientific Officer, specialising in the development of novel molecular entities for critical unmet medical needs.
HPK1 is a key regulator of T cell, B cell and dendritic cell-mediated immune responses, which improves anti-tumour immunity by activating and priming T cells.
GRC 54276 has shown tumour cell killing ability in pre-clinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology, Glenmark said in a statement.
The study will evaluate the safety and tolerability of GRC 54276 as a monotherapy, and also in combination with checkpoint inhibitors in patients with advanced solid tumours and Hodgkin’s lymphoma.
Glenmark will initiate phase-I clinical trial in India by June 2022, and also plans to file an IND in the US and Clinical Trial Applications in Europe to kick-off a fully global clinical study programme, the statement added.
DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine
DCGI gives EUA nod to Covovax for 12-17 years age group
DCGI gives nod to Zydus Oxemia to treat anaemia
DCGI gives nod to manufacture vaccine against omicron for test and analysis
Moderna recalls thousands of C-19 vaccine doses
USFDA gives Zero Observations to SMS Lifesciences
NPPA fixes ceiling price of these two vaccines
Online दवा बिक्री पर रोक लगाए सरकार, CAIT ने लगाई मंत्रियों से गुहार: Must read
After Cosmetics and Blood, now scientists detect microplastics in Lungs
CDSCO gives nod to Mylan to import and market Liposomal Amphotericin…
Indian Ophthalmic Manufacturers stress on importance of USFDA norms
42% of samples detected with prima facie violation of DPCO: Govt
USFDA gives nod to Indoco Remedies for Lacosamide injection
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
